[Clinical and microbiological study of mycetomas at the Muñiz hospital of Buenos Aires between 1989 and 2004].
This work presents clinical, microbiological and outcome data collected from 76 patients with mycetomas at the Muñiz Hospital from 1989 to 2004. Forty-nine patients were male and 27 female; the mean age was 43.4 years. The majority of the patients acquired the infection in Argentina: the most affected provinces were Santiago del Estero with 31 cases, and Chaco with 11; 8 cases came from other countries (Bolivia 6 and Paraguay 2). The mean evolution of the disease was 9.2 years. The most frequently observed sites were: feet 63 cases, ankles 3, and knees 2. Forty-eight patients had bone lesions and 5, adenomegalies. The following etiological agents were identified: Madurella grisea 29 cases, Actinomadura madurae 26, Scedosporium apiospermum 5, Nocardia brasiliensis 5, Acremonium spp. 4 (Acremonium falciforme 2, Acremonium kiliense 1, Acremonium recifei 1), Madurella mycetomatis 3, Fusarium solani 2, Nocardia asteroides 1 and Streptomyces somaliensis 1. The main drugs used in the treatments were ketoconazole and itraconazole for maduromycotic mycetomas, and cotrimoxazole associated with ciprofloxacin or amikacin for actinomycetic mycetoma. Six patients had to undergo amputation, 25 cases achieved complete clinical remission and 34 showed remarkable improvement.
Negroni
R
R
Unidad Micología, Hospital Francisco Javier Muñiz. Uspallata 2272, (1282) Buenos Aires, Argentina. hmmicologia@intramed.net.ar
López Daneri
G
G
Arechavala
A
A
Bianchi
M H
MH
Robles
A M
AM
D000192:Actinomycetales / Q000302:isolation & purification; D000193:Actinomycetales Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D000382:Agricultural Workers' Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000601:surgery; D000671:Amputation, Surgical; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001118:Argentina / Q000453:epidemiology; D003131:Combined Modality Therapy; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000601:surgery; D005670:Fusarium; D006801:Humans; D020461:Madurella / Q000187:drug effects / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D003904:Mitosporic Fungi / Q000302:isolation & purification; D008271:Mycetoma / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000601:surgery; D009617:Nocardia Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000601:surgery; D010000:Osteitis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents